Welcome to our dedicated page for Ufp Technologies SEC filings (Ticker: UFPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The UFP Technologies, Inc. (UFPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. UFP Technologies is a contract development and manufacturing organization specializing in single-use and single-patient medical devices, and its filings offer detailed insight into its operations, financial performance, and risk profile in the medical device supply chain.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include information on net sales, gross profit, operating income, net income, segment performance, and non-GAAP measures such as organic sales growth, adjusted operating income, adjusted net income, and adjusted EBITDA. These filings also contain management’s discussion and analysis and risk factor sections that elaborate on topics referenced in the company’s press releases, including customer concentration, acquisition integration, supply chain and labor considerations, and regulatory and market risks.
Stock Titan also surfaces current reports on Form 8-K, where UFP Technologies furnishes earnings press releases and investor presentation materials under items such as Results of Operations and Financial Condition and Regulation FD Disclosure. These 8-Ks link the narrative in press releases to the formal SEC record and often include exhibits with detailed financial tables and reconciliations.
In addition to core periodic and current reports, users can monitor other SEC documents related to UFP Technologies, including any proxy materials and insider transaction reports when available. Stock Titan enhances these filings with AI-powered summaries that explain key sections in plain language, highlight important changes from prior periods, and help readers quickly locate information on topics such as MedTech versus non-medical sales, acquisition impacts, and capital structure.
UFP Technologies reported significant revenue and profit growth driven largely by recent acquisitions while facing margin pressure, higher interest expense, and customer concentration.
Net sales were $151.2 million for the quarter (up 37.2% year-over-year) and $299.3 million for the six months (up 39.1%). Net income was $17.2 million in the quarter and $34.4 million year-to-date, with diluted EPS of $2.21 for the quarter and $4.42 for six months. Gross margin declined to 28.8% in Q2 from 30.0% due to higher material, labor and onboarding inefficiencies at newly acquired AJR operations. SG&A rose in absolute dollars but decreased as a percentage of sales to 12.4% in Q2.
The company completed multiple acquisitions that expanded its medical-market capabilities and geography, including AJR Enterprises ($110.7M), AQF ($47.7M), Welch ($35.2M), Marble ($5.0M) and AJR Specialty ($2.8M); these collectively contributed about $76.3M in sales in H1 2025. Long-term debt outstanding was $163.6 million with Q2 interest expense of $2.7 million; cash from operations was $39.1 million for six months. Management disclosed contingent consideration obligations, tariff exposure estimated at ~$9 million annually, and customer concentration with two customers representing ~27.4% and ~20.3% of Q2 sales.